NVDA vs LLY
NVIDIA Corporation vs Eli Lilly and Company · Updated Mar 28, 2026
NVDA — 15 winsLLY — 8 wins
Price Performance
NVDA +52.75%LLY +6.78%
Performance
| NVDA | LLY | |
|---|---|---|
| 1 Month | -9.47% | -14.15% |
| 3 Months | -11.25% | -18.53% |
| 6 Months | -5.80% | +22.78% |
| YTD | -10.25% | -18.36% |
| 1 Year | +47.14% | +6.12% |
| 3 Year | +890.50% | +152.20% |
| 5 Year | +1382.60% | +449.95% |
Yearly Returns
| YTD | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| NVDA | -11.3% | +34.8% | +178.8% | +245.9% | -51.5% | +124.3% | +117.7% | +72.4% | -32.9% | +89.8% | +229.9% | +63.7% |
| LLY | -18.7% | +37.4% | +30.4% | +59.7% | +35.1% | +66.9% | +27.7% | +14.4% | +36.7% | +13.2% | -11.3% | +20.3% |
Valuation
| NVDA | LLY | |
|---|---|---|
| P/E Ratio | 34.16 | 38.23 |
| Forward P/E | 21.62 | 26.69 |
| PEG Ratio | 1.08 | 1.85 |
| P/S Ratio | 19.44 | 13.14 |
| P/B Ratio | 26.69 | 32.28 |
| EV/EBITDA | 29.04 | 31.93 |
Financials
| NVDA | LLY | |
|---|---|---|
| EPS (TTM) | $4.90 | $22.95 |
| Gross Margin | +75.00% | +82.52% |
| Operating Margin | +65.02% | +42.85% |
| Net Margin | +63.06% | +34.41% |
| ROE | +76.33% | +77.78% |
| ROA | +58.06% | +18.35% |
| Debt/Equity | 0.07 | 1.60 |
Growth
| NVDA | LLY | |
|---|---|---|
| Revenue Growth YoY | +73.21% | +42.56% |
| Revenue Growth QoQ | +19.51% | +9.61% |
| EPS Growth YoY | +97.75% | +51.43% |
| EPS Growth QoQ | +35.38% | +19.00% |
Technical
| NVDA | LLY | |
|---|---|---|
| RSI (14) | 36.51 | 26.41 |
| % From 20-Day SMA | -6.71% | -8.31% |
| % From 50-Day SMA | -8.78% | -12.88% |
| % From 200-Day SMA | -6.61% | -2.04% |
| % From 52-Week High | -21.12% | -22.63% |
| % From 52-Week Low | +93.24% | +40.66% |
Analyst Ratings
NVDA
Buy(87 analysts)
Strong SellHoldStrong Buy
Price Target
$278.59
+61.85% upside
LLY
Buy(25 analysts)
Strong SellHoldStrong Buy
Price Target
$1243.95
+37.96% upside
Overview
| NVDA | LLY | |
|---|---|---|
| Sector | Technology | Healthcare |
| Industry | Semiconductors | Drug Manufacturers - General |
| Exchange | NASDAQ | NYSE |
| Market Cap | $4.20T | $856.56B |
| Shares Outstanding | 24.31B | 943.4M |
| Avg Volume (10D) | 181.63M | 3.02M |
| Dividend Yield | 0.02% | 0.69% |
Frequently Asked Questions
Is NVDA or LLY a better buy right now?
Based on 23 comparable metrics, NVDA leads in 15 categories while LLY leads in 8. NVDA has a consensus analyst rating with 87 analysts covering the stock. Neither stock should be purchased based on a single comparison — consider your investment goals and risk tolerance.
Which stock has better performance, NVDA or LLY?
Over the past year, NVDA returned +47.14% compared to LLY's +6.12%. In the short term (1 month), NVDA returned -9.47% vs LLY's -14.15%.
Is NVDA or LLY more expensive?
NVDA trades at a P/E of 34.16 compared to LLY's 38.23. On a price-to-sales basis, NVDA trades at 19.44x vs LLY's 13.14x. Forward P/E: NVDA at 21.62 vs LLY at 26.69.
Which stock has higher growth, NVDA or LLY?
NVDA's revenue grew +73.21% year-over-year compared to LLY's +42.56%. EPS growth: NVDA at +97.75% vs LLY at +51.43%.
Do NVDA and LLY pay dividends?
NVDA pays a dividend with a yield of 0.02%. LLY pays a dividend with a yield of 0.69%.
Which stock do analysts prefer, NVDA or LLY?
NVDA has 87 analysts with a target price of $278.59 (+61.85% upside). LLY has 25 analysts with a target of $1243.95 (+37.96% upside).
Data updated daily. All comparisons based on latest available market data. Not investment advice.